FEDERAL COURT OF AUSTRALIA
Biogen International GmbH v Pharmacor Pty Ltd [2021] FCA 1591
Keep reading for free
Create a free CaseChat account to read Biogen International GmbH v Pharmacor Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2021] FCA 1591
- Decision Date
CaseChat Overview and Summary
The Court was required to assess the strength of Biogen's patent infringement case against Pharmacor. This included determining whether the Pharmacor products fell within the scope of the asserted claims of the patent, and whether Pharmacor's anticipated cross-claim for revocation of the asserted claims for invalidity and the assertion that the extension of the term of the patent was invalidly granted, qualified the strength of the infringement case. The Court also had to consider the balance of convenience and justice in deciding whether to grant the interlocutory relief.
The Court found that while Biogen had established a prima facie case for patent infringement, the balance of convenience and justice did not lie in favour of granting the interim relief sought. The Court was satisfied that Pharmacor was unlikely to enter the market before 1 February 2022, and that Biogen's potential loss and damage was not sufficiently quantifiable to warrant the grant of the interlocutory injunction. The Court also found that Pharmacor's arguments regarding the validity of the patent and the extension of its term had merit and warranted further consideration.
The Court dismissed Biogen's interlocutory application, refused to grant the injunction, and ordered that the time for filing an application for leave to appeal from these orders be extended to 31 January 2022. Biogen was also ordered to pay Pharmacor's costs of the application.
Orders
Orders of the court
Upon the respondent undertaking to keep accounts:
1. The applicant’s interlocutory application be dismissed.
2. The time for filing an application for leave to appeal from these orders be extended to 31 January 2022.
3. The applicants pay the respondent’s costs of this application.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
The matter came before the court on an urgent application for interlocutory injunctive relief. Biogen sought an injunction to prevent Pharmacor from listing and supplying its generic products on the PBS, arguing that such action would infringe the Patent and cause irreparable harm. The court heard evidence from several witnesses, including experts in pharmacology, health economics, and forensic accounting, as well as legal counsel. The application was heard and determined by the court, which ultimately decided not to grant the relief sought by Biogen. The court's decision included an extension of time for Biogen to apply for leave to appeal and an order for Biogen to pay Pharmacor's costs of the application.
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Since August 2021, Pharmacor has been preparing for the launch and commencement of the supply of Pharmacor Products from 1 December 2021. As noted above, the Pharmacor Products will not be listed until at least 1 February 2022.1.8 Other ARTG registrations of DMF Accelagen Pty Ltd (Accelagen) is another company with ARTG registration for generic versions of DMF products. Accelagen has four DMF ARTG registrations. On 9 June 2021, Biogen commenced proceedings in this court against Accelagen and MSN Laboratories Private Ltd, India (MSN). On 19 July 2021, the Court made orders by consent enjoining Accelagen and MSN from, amongst other things, seeking listing of the Accelagen DMF products on the PBS whilst the Patent remains in force. Accelagen is not restrained from further transferring its ARTG registrations to third parties. Pursuant to the orders made by Beach J, Accelagen must give Biogen notice, within five days of any transfer of the sponsorship of any of its ARTG registrations to a third party. As a result, at the time of the hearing, Pharmacor was the only generic pharmaceutical company likely to be able to enter the DMF market in Australia on 1 December 2021. Subsequent to the hearing the Court was advised that the earliest date that Pharmacor will be able to enter the market if not restrained is 1 February 2022. 1.9 The issues The dispute concerns the question of the strength of the patent infringement case that Biogen advances and whether the balance of convenience and justice warrants the grant of the interlocutory relief sought. In the amended statement of claim Biogen asserts that the Pharmacor products are pharmaceutical preparations within the scope of at least claims 13, 14, 16, 17, 81, 86, 95, 96, 97 101, 102 and 103 of the Patent. Pharmacor admits that the Pharmacor products fall within the scope of claims 13, 14, 16 (as dependent on 13 or 14), 95, 96, 97, 101(as dependent on claims 95, 96 or 97), 102 (as dependent on any of 95, 96, 97 and 101) and 103 (as dependent on any of claims 95, 96, 97, 101 or 102) of the Patent. Pharmacor denies that the Pharmacor products fall within claims 81 or 86 (both of which are omnibus claims) of the Patent. In light of Pharmacor’s admissions, Biogen does not ask the Court to find a prima facie case of infringement on claims 81 and 86. Pharmacor denies that the Pharmacor products fall within claim 17 which claims a product containing an amount of active ingredient corresponding to 10mg to 300mg of fumaric acid. In the context of the strength the prima facie case the remaining issue on the infringement case is whether claim 17 is infringed. Pharmacor submits that the strength of the infringement case is qualified by its foreshadowed cross-claim for revocation of the asserted claims for invalidity, and the assertion that the extension of term of the Patent was invalidly granted. For the purposes of the interlocutory application, Pharmacor confined its invalidity case at the hearing to a novelty attack to the asserted claims, on the basis of one prior art document: Australian patent application no. 21393/99 (the 593 Application).